The Effects of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy (HYPIC)
Inflammatory Cardiomyopathy, Myocarditis
About this trial
This is an interventional treatment trial for Inflammatory Cardiomyopathy focused on measuring Inflammatory cardiomyopathy, Myocarditis, Hydroxychloroquine, Randomized controlled trial
Eligibility Criteria
Inclusion Criteria: Age 18-80 years; Heart failure NYHA II-IV; Patients with myocarditis confirmed by myocardial biopsy in the past; Standard treatment for heart failure > 6 months; Persistent reduction of LVEF <50% on a routine echocardiographic evaluation (Simpson's biplane) not older than 1 month at time of inclusion; hs-cTnI >26.5pg/mL or NT-proBNP>169 pg/mL; Exclusion Criteria: Age <18 or >80 years; Known or possible systemic inflammatory disease; Patient on the brink of death or life expectancy<1 year; Drug or alcohol abuse; Pregnancy or lactation; Patients who cannot persist in taking medication due to various reasons; Inability to provide informed consent;
Sites / Locations
- Tongji HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
HCQ group
GC group
Hydroxychloroquine 200mg bid and Prednisolone 15mg qd for a long time (more than 1 year)
Prednisolone 15mg qd for a long time (more than 1 year)